Last Week in Biomedicine

Part 2 covers three more standout stories from the same week: a Phase 3 trial that gives babies with a devastating enzyme disease a fighting chance, a first-of-its-kind cell therapy approved to make bone-marrow transplants safer, and a new lymphoma combination that could give aggressive-blood-cancer patients another option after other therapies fail. In Part 2 we cover: 4. Sanofi — Nexviazyme (ava...

CRISPR gene editing crossed a major line this week: the FDA now allows Casgevy — the first CRISPR therapy of any kind — for children as young as 2 with sickle cell disease, meaning we can potentially prevent a lifetime of pain crises and organ damage instead of treating them after the fact. Part 1 also digs into a rare kind of trial where a new lung cancer drug takes on the already-approved compet...

Part 2 covers a new drug for the bulging-eye autoimmune disease, the first Phase 3 ADHD trial designed for patients who also have anxiety, and a major pediatric expansion for a top-selling psoriasis biologic. In Part 2 we cover: 4. Viridian Therapeutics — Lumvoa (veligrotug) for thyroid eye disease, active and chronic (FDA approval) 5. Otsuka Pharmaceutical — centanafadine for adult ADHD with como...

This week, an LSD-based therapy hit its main goal in a Phase 3 depression trial — and two huge breast cancer approvals landed at the FDA on the same week. In Part 1 we cover: 1. Definium Therapeutics — DT120 (LSD-based orally disintegrating tablet) for major depressive disorder (Phase 3) 2. Gilead Sciences / Merck — Trodelvy (sacituzumab govitecan) ± Keytruda for first-line PD-L1+ metastatic tripl...

Part 2 of our week of June 14–20, 2026 wrap-up covers a new molecular glue for relapsed multiple myeloma that cut disease progression by half, a heart drug that may finally work forboth forms of hypertrophic cardiomyopathy, and a new combination regimen poised to upgrade the first-line standard of care in myelofibrosis. In Part 2 we cover:4. Bristol Myers Squibb — Mezigdomide for relapsed/refracto...

This week opened with one of the most significant gene-editing milestones in clinical medicine: a single CRISPR infusion cut hereditary angioedema attacks by 87 percent in a Phase 3 trial, published the same day in the New England Journal of Medicine. Plus a first-in-class drug that may reshape how we treat narcolepsy, and the first new oral antifungal class in over 20 years. In Part 1 we cover: 1...

Part 2 of our June 6–13 wrap-up: Novo Nordisk's CagriSema beats semaglutide alone in three Phase 3 diabetes trials, Takeda's zasocitinib pill outperforms Sotyktu head-to-head in psoriasis, and Agios's mitapivat headlines the EHA Plenary with breakthrough Phase 3 sickle cell data. In Part 2 we cover: 4. Novo Nordisk — CagriSema (cagrilintide + semaglutide) for type 2 diabetes (Phase 3)...

A blockbuster week in biomedicine — Eli Lilly's retatrutide produced weight loss approaching bariatric surgery in Phase 3, and Gilead and Merck's once-weekly oral HIV pill cleared two Phase 3 trials. Plus the first in-vivo CRISPR therapy keeps stacking up Phase 3 wins. In Part 1 we cover:1. Eli Lilly — Retatrutide for obesity (Phase 3) 2. Gilead Sciences and Merck — Islatravir/Lenacapavir...

From a prostate cancer combo that uses your tumor's own broken DNA-repair against it, to the first drug ever to succeed in a rare autoimmune disease called IgG4-related disease — Part 2 of our weekly biomedicine recap covers three more major readouts from the week of May 30 – June 5, 2026. In Part 2 we cover: 4. Pfizer — Talazoparib plus enzalutamide for metastatic castration-sensitive prostat...

The biggest week in cancer research of 2026 dropped at the ASCO meeting in Chicago, and one drug stole the show: a new RAS-blocking pill that nearly doubled survival in metastatic pancreatic cancer, one of the deadliest diseases in medicine. In Part 1 we cover: 1. Revolution Medicines — Daraxonrasib for metastatic pancreatic cancer (Phase 3) 2. Summit Therapeutics and Akeso — Ivonescimab for first...

In Part 2 we cover the remaining clinical trial readouts from the week of May 23–29, 2026 — a Phase 2 atopic dermatitis breakthrough and a Phase 3 multiple sclerosis convenience win. 4. Apogee Therapeutics — Zumilokibart for Moderate-to-Severe Atopic Dermatitis (Phase 2) 5. TG Therapeutics — BRIUMVI (ublituximab-xiiy) for Relapsing Forms of Multiple Sclerosis (Phase 3 ENHANCE) Apogee Therapeutics...

In Part 1 we cover the three biggest clinical trial readouts from the week of May 23–29, 2026 — including two ASCO 2026 opening-day announcements that reshape oncology. 1. Bristol Myers Squibb — Mezigdomide for Relapsed or Refractory Multiple Myeloma (Phase 3) 2. GSK — Bepirovirsen for Chronic Hepatitis B Infection (Phase 3) 3. Pfizer — LORBRENA (lorlatinib) for ALK-Positive Non-Small-Cell Lung Ca...

Part 2 of our May 18–22, 2026 roundup digs into a first-in-class Bicycle Toxin Conjugate for bladder cancer, a non-surgical DNA immunotherapy clearing HPV-driven cervical pre-cancer, anoff-the-shelf cancer vaccine extending remission in ovarian cancer, an engineered IL-2 antibody pulling responses out of melanoma that had resisted every checkpoint inhibitor, and a topical hair-loss drug that may f...

This week the biggest story in clinical trial results came out of an obesity trial: Eli Lilly's retatrutide — a once-weekly shot that activates three different appetite-and-metabolism hormones (GIP, GLP-1, and glucagon) at the same time — helped adults with obesity lose an average of roughly 30% of their body weight at 80 weeks. That level of weight loss was previously only seen with bariatric sur...

Top 10 significant clinical trial results from last week Part 2: 6. Enterprise Therapeutics (private) — ETD001 (inhaled ENaCblocker) for cystic fibrosis (Phase 2) 7. Daré Bioscience ($DARE) — Ovaprene (hormone-free monthly intravaginal contraceptive) for contraception (Phase 3) 8. Candel Therapeutics ($CADL) — aglatimagene besadenovec (CAN-2409) for localized prostate cancer (Phase 3) 9. Alpha Tau...

Top 10 significant clinical trial results from last week Part 1: 1. REGENXBIO ($RGNX) — RGX-202 microdystrophin gene therapy for Duchenne muscular dystrophy (Phase 3) 2. Alkermes ($ALKS) — LUMRYZ (sodium oxybate once-nightly) for idiopathic hypersomnia (Phase 3) 3. Viking Therapeutics ($VKTX) — oral VK2735 (GLP-1/GIP dual agonist) for obesity (Phase 2) 4. Inhibrx Biosciences ($INBX) — INBRX-106 (h...

Last week's biggest biotech story: Cytokinetics hit both dual primary endpoints in the ACACIA-HCM pivotal Phase 3 trial of aficamten in non-obstructive hypertrophic cardiomyopathy — the first cardiac myosin inhibitor to win in nHCM and a major franchise expansion. Moderna's mRNA-1010 flu vaccine also landed in NEJM, and DDW 2026 drove a cluster of IBD readouts. This week we cover: 1. Cytok...